CytomX Therapeutics, Inc. (CTMX) Dividend History

CytomX Therapeutics, Inc. is a biotechnology company focused on developing innovative cancer treatments using its proprietary Probody technology. This platform employs antibody masks that remain inactive until they reach the tumor site, aiming to improve safety and efficacy by reducing off-target effects. Founded in 2011 and based in South San Francisco, CytomX collaborates with various pharmaceutical partners to advance immuno-oncology and targeted cancer therapies.

151 Oyster Point Blvd., South San Francisco, CA, 94080
Phone: 650.515.3185
Website: https://www.cytomx.com

Dividend History

CytomX Therapeutics, Inc. currently does not pay dividends

Company News

CytomX Therapeutics Presents Preclinical Data for mRNA Encoded Masked IL-12 Molecule in Collaboration with Moderna at AACR Annual Meeting

CytomX Therapeutics and Moderna presented preclinical data on an mRNA-encoded masked IL-12 molecule, which showed potent anti-tumor activity with enhanced tolerability.

GlobeNewswire Inc.

Featured Companies: MRNA
CytomX Therapeutics to Present at the Barclays 27th Annual Global Healthcare Conference

CytomX Therapeutics, a biopharmaceutical company focused on developing novel conditionally activated biologics for cancer treatment, announced that its CEO will present at the Barclays Global Healthcare Conference. The company's pipeline includes several clinical-stage candidates targeting various cancer types.

GlobeNewswire Inc.
CytomX Therapeutics Promotes Chris Ogden to Chief Financial Officer

SOUTH SAN FRANCISCO, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced the promotion of Chris Ogden to Chief Financial Officer effective June 15, 2024.

GlobeNewswire Inc.
CytomX Therapeutics to Present at the Jefferies Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will present at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024, at 8:30 a.m. ET.

GlobeNewswire Inc.
CytomX Therapeutics Announces New Employment Inducement Grants

SOUTH SAN FRANCISCO, Calif., May 16, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that on May 15, 2024, the Company granted two new employees options to purchase a total of 130,000 shares of the Company’s common stock at an exercise price per share equal to $1.96, which was the closing price on May 15, 2024, the date of the grants.

GlobeNewswire Inc.

Dividend data last updated 06/07/2025 20:06:39 UTC